Breaking Finance News

Janney Capital downgraded NanoString Technologies (NASDAQ:NSTG) from Buy to Neutral in a report released today.

Just yesterday NanoString Technologies (NASDAQ:NSTG) traded -37.04% lower at $15.66. NanoString Technologies’s 50-day moving average is $15.72 and its 200-day moving average is $16.63. The last stock price is down -40.71% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 745,970 shares of NSTG traded hands, up from an average trading volume of 170,649

Janney Capital has downgraded NanoString Technologies (NASDAQ:NSTG) from Buy to Neutral in a report released on Thursday October 12, 2017.

Recent Performance Chart

NanoString Technologies (NASDAQ:NSTG)

NanoString Technologies has 52 week low of $9.81 and a 52 week high of $23.45 and has a market cap of $0.

In addition to Janney Capital reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $19.20 with 3 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About NanoString Technologies (NASDAQ:NSTG)

NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company's nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *